Top Markets
#1 MON MON +2,760.99%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.39%
#4 eCash eCash +37.30%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.18%
#7 Collector Crypt Collector Crypt +23.96%
#8 SAFEcoin SAFEcoin +19.72%
#9 Janction Janction +19.66%
#10 Velvet Velvet +15.56%
Coin of the day
MON MON
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Classement en actions #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Prix de l'action
$0.30840035
Capitalisation boursière
$94.37M
Changement (1 jour)
0.00%
Changement (1 an)
-34.60%
Pays
FR
Échange Sensorion SA (ALSEN)

Catégorie

Healthcare
Ratio P/S pour Sensorion SA (ALSEN)
Ratio P/S au July 2026 TTM : 31.10
Selon les derniers rapports financiers et le cours de l'action de Sensorion SA, le ratio cours/ventes actuel (TTM) est 31.10. À la fin de 2023, le ratio P/S était de 10.07.
Historique du ratio P/S pour Sensorion SA de 2011 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 31.10 14.55%
2024 27.15 169.61%
2023 10.07 68.16%
2022 5.99 -83.37%
2021 36.00 -7.10%
2020 38.75 504.07%
2019 6.41 24.60%
2018 5.15 -64.35%
2017 14.44 -99.23%
2016 1.87K 702.80%
2015 233.19 264.53%
2014 63.97 53.97%
2013 41.55 -35.02%
2012 63.94 -99.99%
2011 705.41K 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.26 -86.29%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.29 -66.92%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.31 -86.16%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.44 -79.28%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.96 -45.47%
NL